Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Dec 31;1(12):1363-1372.
doi: 10.34067/KID.0004002020.

Baseline Characteristics and Patient-Reported Outcomes of ADPKD Patients in the Multicenter TAME-PKD Clinical Trial

Stephen L Seliger #  1 , Terry Watnick #  1 , Andrew D Althouse  2 , Ronald D Perrone  3 , Kaleab Z Abebe  2 , Kenneth R Hallows  4 , Dana C Miskulin  2 , Kyongtae T Bae  3   5
Affiliations
Clinical Trial

Baseline Characteristics and Patient-Reported Outcomes of ADPKD Patients in the Multicenter TAME-PKD Clinical Trial

Stephen L Seliger et al. Kidney360. .

Abstract

Background: Autosomal dominant polycystic kidney disease (ADPKD) has been associated with metabolic disturbances characterized by downregulation of AMP-activated protein kinase (AMPK), a critical sensor of the cellular energy status. Therapeutic activation of AMPK by metformin could inhibit cyst enlargement by inhibition of both the mammalian target of rapamycin pathway and fluid secretion via the CFTR chloride channel.

Methods: We designed a phase-2, randomized, placebo-controlled, clinical trial to assess the safety, tolerability, and efficacy of metformin on total kidney volume in adults without diabetes (age 18-60 years) with ADPKD and eGFR of ≥50 ml/min per 1.73 m2. There were no eligibility criteria relating to kidney volume. In addition to demographics and clinical/family history, baseline parameters included eGFR, total kidney and liver volumes measured by MRI, and patient-reported outcomes were ascertained by the Medical Outcomes Study Short Form-36, the Gastrointestinal Safety Rating Scale, and the HALT-PKD pain questionnaire.

Results: We successfully randomized 97 participants recruited from two university-based clinical sites in Baltimore and Boston. The mean age of participants was 41.9 years, 72% were female, and 94% of participants were White. The majority of study participants had early stage disease, with a mean eGFR of 86.8±19.0 ml/min per 1.73 m2. Approximately half of the study participants (48%) were classified as high risk for progression (Mayo imaging classes 1C, 1D, or 1E). There was no correlation between kidney and/or liver size and health-related quality of life (HRQoL) or gastrointestinal symptom severity.

Conclusions: We report successful recruitment in this ongoing, novel, clinical trial of metformin in ADPKD, with a study sample comprising patients with early stage disease and nearly a half of participants considered at high estimated risk for progression. Participants reported a low gastrointestinal symptom burden at baseline, and HRQoL similar to that of the general population, with no differences in symptoms or HRQoL related to organomegaly.

Clinical trial registry name and registration number: Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease (TAME), NCT02656017.

PubMed Disclaimer

Conflict of interest statement

K. Bae is a consultant to Kadmon Corporation, Otsuka, and Sanofi. R. Perrone is a consultant to Otsuka, Palladiobio, Reata, Sanofi-Genzyme, and Vertex. R. Perrone serves as the editor of the renal cystic disease section for UpToDate. T. Watnick has a patent to Athena Diagnostics issued, is on the scientific advisory committee of the PKD Foundation (no financial relationship), serves in an advisory capacity as chair of the advisory committee to the PKD Foundation’s ADPKD registry (no financial relationship). All remaining authors have nothing to disclose.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Flow of participants from screening to randomization. NOS, not otherwise specified; MRI, magnetic resonance imaging.
Figure 2.
Figure 2.
Height-adjusted kidney volume was not associated with health-related quality of life. (A) Short Form-36 (SF-36) mental composite score (MCS) and height-adjusted total kidney volume (htTKV). (B) SF-36 physical composite score (PCS) and htTKV.
See this image and copyright information in PMC

References

    1. Harris PC, Torres VE: Polycystic kidney disease. Annu Rev Med 60: 321–337, 2009 - PMC - PubMed
    1. Grantham JJ: Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 359: 1477–1485, 2008 - PubMed
    1. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr., Wetzel LH, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zhu F, Miller JP; CRISP Investigators : Volume progression in polycystic kidney disease. N Engl J Med 354: 2122–2130, 2006 - PubMed
    1. Luciano RL, Dahl NK: Extra-renal manifestations of autosomal dominant polycystic kidney disease (ADPKD): Considerations for routine screening and management. Nephrol Dial Transplant 29: 247–254, 2014 - PubMed
    1. Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S, Kasiske BL, Odland D, Pei Y, Perrone RD, Pirson Y, Schrier RW, Torra R, Torres VE, Watnick T, Wheeler DC; Conference Participants : Autosomal-dominant polycystic kidney disease (ADPKD): Executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int 88: 17–27, 2015 - PMC - PubMed

Publication types

Associated data